Every Form 4 that Lineage Cell Therapeutics, Inc. (LCTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LCTX filings page.
Lineage Cell Therapeutics director and 10% owner Neal C. Bradsher reported a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. They were granted on July 1, 2026 as director compensation under Lineage’s 2021 Equity Incentive Plan.
According to the filing, these options will vest and become exercisable on the earlier of July 1, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. The report also lists several existing option holdings with exercise prices between $0.8263 and $2.86 per share, expiring from 2029 through 2035.
Lineage Cell Therapeutics director Anula Jayasuriya received a stock option grant covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option will vest and become exercisable on the earlier of July 1, 2027 and the company’s next annual meeting of shareholders, subject to Jayasuriya’s continuous service with the company. Following this grant, the filing shows 125,000 derivative securities held directly.
Lineage Cell Therapeutics director Michael H. Mulroy received a grant of stock options representing 125,000 common shares. The options carry an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase or sale.
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of the company’s next annual shareholder meeting, subject to his continuous service with the company.
Lineage Cell Therapeutics director Deborah J. Andrews received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.3000 per share and expire on July 1, 2036. They were awarded as a compensation-related grant rather than an open-market purchase or sale.
According to the terms, the options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage Cell Therapeutics' next annual meeting of shareholders, provided Andrews continues to serve the company through that time. Following this grant, she holds stock options for 125,000 shares directly.
Lineage Cell Therapeutics director Russell Angus received a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036.
According to the footnote, the options will vest and become exercisable on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual meeting of shareholders, in each case only if he continues to serve with the company. After this grant, his reported derivative holdings from this award total 125,000 options.
Lineage Cell Therapeutics director Dipti Amin received a stock option grant covering 125,000 common shares. The option has an exercise price of $1.30 per share and expires on July 1, 2036. It will vest and become exercisable on the earlier of July 1, 2027 and the date of the company’s next annual shareholder meeting, subject to Amin’s continuous service. Following this grant, Amin holds options for 125,000 shares directly.
Lineage Cell Therapeutics President and CEO Brian M. Culley reported an open-market purchase of 15,000 common shares at a weighted average price of $1.625 per share. Following these purchases, he directly holds 255,516 common shares.
Lineage Cell Therapeutics reported that its President and CEO, Brian M. Culley, received a grant of stock options covering 3,250,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the terms, one quarter of these options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments thereafter, contingent on continued employment. Following this award, Culley holds 3,250,000 stock options directly.
Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026. These options carry a stated exercise price of $0.0000 per share, reflecting a compensatory award rather than an open-market purchase.
According to the terms, one quarter of the options will vest on March 5, 2027. The remaining three quarters will then vest in 36 equal monthly installments, contingent on the completion of each month of continuous employment. Following this grant, Howe’s directly held option position from this award totals 1,050,000 options.
Samuel George A. III reported acquisition or exercise transactions in this Form 4 filing.
Lineage Cell Therapeutics, Inc. reported that its General Counsel and Secretary, Samuel George A. III, received a grant of 900,000 employee stock options on March 5, 2026. These options were awarded at no purchase price at grant as part of his compensation.
According to the vesting terms, one quarter of the options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments after that date, contingent on continuous employment each month.
Culley Brian M reported multiple insider transaction types in a Form 4 filing for LCTX. The filing lists transactions totaling 75,369 shares at a weighted average price of $1.80 per share. Following the reported transactions, holdings were 240,516 shares.
Samuel George A. III reported multiple insider transaction types in a Form 4 filing for LCTX. The filing lists transactions totaling 14,652 shares at a weighted average price of $1.80 per share. Following the reported transactions, holdings were 31,063 shares.
Lineage Cell Therapeutics, Inc. reported an insider equity transaction by its President and CEO and Director, Brian M. Culley. On 12/19/2025, he earned 8,925 common shares upon vesting of restricted stock units that were granted on February 11, 2022, which were subject to performance conditions. These RSUs are settled in common shares on a one-for-one basis.
On the same date, 334 shares were withheld by the company at a price of $1.68 per share to cover statutory tax withholding obligations related to the vesting. After these transactions, Culley beneficially owned 222,135 common shares directly. The disclosure notes that this amount does not include unvested RSUs or shares that could be acquired through outstanding stock options.
Lineage Cell Therapeutics, Inc. reported an insider equity transaction by its General Counsel and Secretary, George A. Samuel III. On 12/19/2025, he acquired 1,735 common shares through the vesting of previously granted performance-based restricted stock units, which convert into common shares on a one-for-one basis. The company then withheld 65 shares at $1.68 per share to cover statutory tax obligations related to this vesting, with no shares sold on the open market.
Following these transactions, Samuel directly beneficially owned 27,490 common shares of Lineage Cell Therapeutics. The filing notes that this total does not include any unvested restricted stock units or shares that could be acquired through outstanding stock options that remained unexercised as of the report date.